Search

Your search keyword '"Avezum Jr, A."' showing total 3 results
Start Over Author "Avezum Jr, A." Database OpenAIRE
3 results on '"Avezum Jr, A."'

1. Five-year cardiovascular outcomes in patients with chronic myeloid leukemia treated with imatinib, dasatinib, or nilotinib: A cohort study using data from a large multinational collaborative network

Author

Rafael Amorim Belo Nunes, Precil Diego Miranda de Menezes Neves, Leandro Menezes Alves da Costa, Philip Bachour, Marcelo José de Carvalho Cantarelli, Gustavo Bernardes de Figueiredo Oliveira, and Álvaro Avezum Jr.

Subjects
Cardiology and Cardiovascular Medicine
Abstract

BackgroundBreakpoint cluster region-Abelson gene (BCR-ABL) tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of patients with chronic myeloid leukemia (CML). However, concern has arisen about the cardiac safety profile of these drugs.ObjectivesThis study aims to compare long-term risks of adverse cardiovascular and cerebrovascular events (ACE), heart failure or left ventricular ejection fraction (LVEF) < 50%, and venous thromboembolic events (VTE) in patients with CML treated with BCR-ABL TKIs, using data from a large multinational network.MethodsPatients aged ≥ 18 years with CML treated with imatinib, dasatinib, or nilotinib without prior cardiovascular or cerebrovascular disease were included. We used propensity score matching to balance the cohorts. The 5-year cumulative incidences and hazard ratios were calculated.ResultsWe identified 3,722 patients with CML under treatment with imatinib (n = 1,906), dasatinib (n = 1,269), and nilotinib (n = 547). Patients with imatinib compared to dasatinib showed a higher hazard ratio (HR) for ACE (HR 2,13, 95% CI 1.15–3.94, p = 0.016). Patients with imatinib presented a lower HR than nilotinib for ACE (HR 0.50, 95% CI 0.30–0.83, p = 0.0074). In relation to heart failure or LVEF < 50%, patients with imatinib had a higher HR than dasatinib (HR 9.41, 95% CI 1.22–72.17, p = 0.03), but no significant difference was observed between imatinib and nilotinib (HR 0.48, 95% CI 0.215–1.01, p = 0.064).ConclusionIn this retrospective study with a large number of patients with CML, those treated with nilotinib had a higher 5-year ratio of ACE, while patients with dasatinib showed a lower ratio than patients with imatinib. The ratio of heart failure was higher in patients with imatinib than in patients with dasatinib, but not when compared to nilotinib.

Published
2023
Full Text
View/download PDF

2. [Brazilian guidelines on platelet antiaggregants and anticoagulants in cardiology].,Diretrizes brasileiras de antiagregantes plaquetários e anticoagulantes em cardiologia

Author

Sociedade Brasileira de Cardiologia, Lorga Filho, A. M., Azmus, A. D., Soeiro, A. M., Quadros, A. S., Avezum Jr, A., Marques, A. C., Franci, A., Manica, A. L., Volschan, A., Paola, A. A., Greco, A. I., Ferreira, A. C., Sousa, A. C., Pesaro, A. E., Simão, A. F., Lopes, A. S., Timerman, A., Ramos, A. I., Alves, B. R., Caramelli, B., Mendes, B. A., Polanczyk, C. A., Montenegro, C. E., Barbosa, C. J., Serrano Jr, C. V., Melo, C. C., Pinho, C., Moreira, D. A., Calderaro, D., Gualandro, D. M., Armaganijan, D., Machado Neto, E. A., Bocchi, E. A., Paiva, E. F., Stefanini, E., D Amico, E., Evaristo, E. F., Silva, E. E., Fernandes, F., Brito Jr, F. S., Bacal, F., Ganem, F., Gomes, F. L., Mattos, F. R., Moraes Neto, F. R., Tarasoutchi, F., FRANCISCO DARRIEUX, Feitosa, G. S., Fenelon, G., Morais, G. R., Correa Filho, H., Castro, I., Gonçalves Jr, I., Atié, J., Souza Neto, J. D., Ferreira, J. F., Nicolau, J. C., Faria Neto, J. R., Annichino-Bizzacchi, J. M., Zimerman, L. I., Piegas, L. S., Pires, L. J., Baracioli, L. M., Silva, L. B., Mattos, L. A., Lisboa, L. A., Magalhães, L. P., Lopes, M. A., Montera, M. W., Figueiredo, M. J., Malachias, M. V., Gaz, M. V., Andrade, M. D., Bacellar, M. S., Barbosa, M. R., Clausell, N. O., Dutra, O. P., Coelho, O. R., Yu, P. C., Lavítola, P. L., Lemos Neto, P. A., Andrade, P. B., Farsky, P. S., Franco, R. A., Kalil, R. A., Lopes, R. D., Esporcatte, R., Heinisch, R. H., Kalil Filho, R., Giraldez, R. R., Alves, R. C., Leite, R. E., Gagliardi, R. J., Ramos, R. F., Montenegro, S. T., Accorsi, T. A., Jardim, T. S., and Scudeler, T. L.

3. [Brazilian guidelines on platelet antiaggregants and anticoagulants in cardiology]. | Diretrizes brasileiras de antiagregantes plaquetários e anticoagulantes em cardiologia

Author

Sociedade Brasileira de Cardiologia, Lorga Filho, A. M., Azmus, A. D., Soeiro, A. M., Quadros, A. S., Avezum Jr, A., Marques, A. C., Franci, A., Manica, A. L., Volschan, A., Paola, A. A., Greco, A. I., Ferreira, A. C., Sousa, A. C., Pesaro, A. E., Simão, A. F., Lopes, A. S., Timerman, A., Ramos, A. I., Alves, B. R., Caramelli, B., Mendes, B. A., Polanczyk, C. A., Montenegro, C. E., Barbosa, C. J., Serrano Jr, C. V., Melo, C. C., Pinho, C., Moreira, D. A., Calderaro, D., Gualandro, D. M., Armaganijan, D., Machado Neto, E. A., Bocchi, E. A., Paiva, E. F., Stefanini, E., D Amico, E., Evaristo, E. F., Silva, E. E., Fernandes, F., Brito Jr, F. S., Bacal, F., Ganem, F., Gomes, F. L., Mattos, F. R., Moraes Neto, F. R., Tarasoutchi, F., Darrieux, F. C., Feitosa, G. S., Fenelon, G., Morais, G. R., Correa Filho, H., Castro, I., Gonçalves Jr, I., Atié, J., Souza Neto, J. D., Ferreira, J. F., Nicolau, J. C., Faria Neto, J. R., Annichino-Bizzacchi, J. M., Zimerman, L. I., Leopoldo Piegas, Pires, L. J., Baracioli, L. M., Silva, L. B., Mattos, L. A., Lisboa, L. A., Magalhães, L. P., Lopes, M. A., Montera, M. W., Figueiredo, M. J., Malachias, M. V., Gaz, M. V., Andrade, M. D., Bacellar, M. S., Barbosa, M. R., Clausell, N. O., Dutra, O. P., Coelho, O. R., Yu, P. C., Lavítola, P. L., Lemos Neto, P. A., Andrade, P. B., Farsky, P. S., Franco, R. A., Kalil, R. A., Lopes, R. D., Esporcatte, R., Heinisch, R. H., Kalil Filho, R., Giraldez, R. R., Alves, R. C., Leite, R. E., Gagliardi, R. J., Ramos, R. F., Montenegro, S. T., Accorsi, T. A., Jardim, T. S., and Scudeler, T. L.

Catalog

Books, media, physical & digital resources
See catalog results